FLINT, Mich., Dec. 1, 2016 /PRNewswire/ -- Diplomat
Pharmacy, Inc. (NYSE: DPLO) announced today that it will be
dispensing DARZALEX® (daratumumab) in combination with
REVLIMID® (lenalidomide) and dexamethasone or with
VELCADE® (bortezomib) and dexamethasone.
DARZALEX was recently approved by the Food and Drug
Administration to treat patients with multiple myeloma who have
received at least one other treatment.
The FDA had previously approved DARZALEX to treat patients who
have received three prior lines of therapy, including a proteasome
inhibitor (PI) and an immunomodulatory agent, or those who are
resistant to both a PI and an immunomodulatory agent.
To learn more about Diplomat's oncology program, visit
diplomat.is/areas-of-excellence/oncology.
DARZALEX is a monoclonal antibody that works with the immune
system. It attaches to a protein called CD38, on the surface of
many myeloma cells. Once DARZALEX attaches to the CD38 protein, it
helps the immune system find and kill myeloma cells. DARZALEX is
the first anti-CD38 in the world approved for humans.
"At Diplomat, we are focused on providing excellent care to
every single patient," said Paul
Urick, Diplomat's president. "With DARZALEX, we are able to
offer a treatment to our multiple myeloma patients who have tried
at least one other therapy. Along the way, our oncology team of
pharmacists, nurses, and care coordinators works hard to provide a
consistent high level of care to support them at all times as they
grapple with multiple myeloma."
Multiple myeloma is a hematological (blood) cancer in which
malignant plasma cells form in the bone marrow, producing abnormal
proteins. Because plasma cells circulate widely in the body, they
can affect many bones and result in compression fractures, lytic
bone lesions, and related pain. According to the American Cancer
Society, about 30,330 Americans will be diagnosed with multiple
myeloma in 2016.
DARZALEX is manufactured by Janssen Biotech, Inc. For full
prescribing information on DARZALEX, click here.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements give
current expectations or forecasts of future events or our future
financial or operating performance. The forward-looking
statements contained in this press release are based on
management's good-faith belief and reasonable judgment based on
current information. These statements are qualified by
important risks and uncertainties, many of which are beyond our
control, that could cause our actual results to differ materially
from those forecasted or indicated by such forward-looking
statements. For a discussion of such risks and uncertainties, you
should review Diplomat's filings with the Securities and Exchange
Commission, including "Risk Factors" in Diplomat's Annual Report on
Form 10-K for the year ended December 31,
2015 and in subsequent reports filed with or furnished to
the Securities and Exchange Commission. Except as may be
required by any applicable laws, Diplomat assumes no obligation to
publicly update such forward-looking statements, which are made as
of the date hereof or the earlier date specified herein, whether as
a result of new information, future developments or otherwise.
About Diplomat
Diplomat (NYSE: DPLO) serves patients and physicians in all 50
states. Headquartered in Flint,
Michigan, the company focuses on medication management
programs for people with complex chronic diseases, including
oncology, immunology, hepatitis, multiple sclerosis, specialized
infusion therapy and many other serious or long-term conditions.
Diplomat opened its doors in 1975 as a neighborhood pharmacy with
one essential tenet: "Take good care of patients and the rest falls
into place." Today, that tradition continues—always focused on
improving patient care and clinical adherence. For more information
visit diplomat.is.
CONTACT:
Kali Lucas,
Public Relations Specialist
810.768.9580 | press@diplomat.is
Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is
Logo - http://photos.prnewswire.com/prnh/20140928/148820
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/diplomat-to-dispense-multiple-myeloma-combination-drug-darzalex-300371735.html
SOURCE Diplomat Pharmacy, Inc.